Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences researches. The Company offers research tools and examination material, including diagnostic kits and ethical drugs.

Non-Consolidated Financial Results (Japanese Gaap) For The Nine Months Ended September 30, 2025

Supplementary Information For Financial Results Q3 Fy12/25

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chiome Bioscience (4583 JP)

Non-Consolidated Financial Results (Japanese Gaap) For The Nine Months Ended September 30, 2025

Supplementary Information For Financial Results Q3 Fy12/25

Non-Consolidated Financial Results (Japanese Gaap) For The Six Months Ended June 30,2025

Supplementary Information For Financial Results Q2 Fy12/25

Non-Consolidated Financial Results (Japanese Gaap) For The Three Months Ended March 31,2025

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)